Core Viewpoint - The eighth China International Import Expo (CIIE) showcased Novo Nordisk's commitment to obesity management through its product Ozempic® and the "Lightweight House" experience, aiming to enhance public awareness of obesity as a serious chronic disease [1][3]. Group 1: Product and Initiative Highlights - Novo Nordisk presented its star product, Ozempic®, which is used for long-term weight management, at the CIIE [1]. - The "Lightweight House" experience introduced a full-cycle scenario of "cognitive enhancement, scientific treatment, and long-term management" to raise awareness about obesity [3]. - The company launched the initiative "Scientific Weight Loss, Healthy Lightweight" to promote understanding and practices in obesity prevention and treatment [1][3]. Group 2: Scientific and Community Engagement - The "Cognitive Enhancement" segment utilized AI visual recognition technology to help the public visualize their weight gain and understand the associated health risks [3]. - The "Scientific Treatment" section showcased a new model of "hospital-retail collaboration" to improve the management of obesity, emphasizing the role of GLP-1 weight loss medications like semaglutide [3]. - The "Long-term Management" aspect highlighted the importance of digital solutions in ongoing obesity management through Novo Nordisk's patient service platform, "Novo Care" [3]. Group 3: Expert Insights and Public Health Perspective - Experts emphasized that obesity is a misunderstood chronic disease requiring comprehensive support across health education, lifestyle interventions, and clinical treatments [4]. - The importance of long-term commitment to weight loss was underscored, with a call for societal collaboration to address obesity as a public health issue [5]. - Novo Nordisk's leadership expressed a commitment to providing integrated solutions for patients' weight loss journeys and fostering a collaborative ecosystem for obesity prevention in China [5].